SCHEMBL2179263

SCHEMBL2179263

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4ccccc4Cl)cn3)cc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.44
CSGALNACT1 Q8TDX6 1/20 0.43
SDCBP O00560 2/20 0.42
SDC2 P34741 2/20 0.42
LMNA P02545 3/20 0.41
THRB P10828 1/20 0.41
TP53 P04637 2/20 0.41
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 6/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LCK P06239 1/20 0.39
HCK P08631 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719602 1.00 DGAT1 (0.44) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL2180429 0.92 LMNA (0.43) DGAT1CSGALNACT1LMNATHRBTP53
SCHEMBL2176697 0.86 DGAT1 (0.51) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL13718751 0.86 DGAT1 (0.51) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL13718779 0.85 DGAT1 (0.43) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL2176926 0.85 DGAT1 (0.43) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL2364244 0.84 KDR (0.42) DGAT1LMNAMEN1NPC1RAB9A
SCHEMBL2177496 0.84 KDR (0.42) DGAT1LMNAMEN1NPC1RAB9A
SCHEMBL13718763 0.84 DGAT1 (0.44) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL2177914 0.84 DGAT1 (0.44) DGAT1CSGALNACT1SDCBPSDC2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885CSGALNACT1 783/4885SDCBP 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.